ReviewFrontiers in oncology2020
Advances in Radiobiology of Stereotactic Ablative Radiotherapy.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 61 citations in OpenAlex.
- Article
- High-accuracy quality control method of CT system couch tops for treatment planning via an advanced 3D coordinate measuring machine.Journal of applied clinical medical physics · 2025Article
- MiR-26b-5p mediates radioresistance and immunosuppression via targeting PRKCD in non-small cell lung cancer.Journal of cancer research and clinical oncology · 2025Article
- Article
- A novel microdosimetry-based formalism for cell survival modelling applicable to hypofractionated radiotherapy.Physics in medicine and biology · 2025Article
- Review
- [Advances in the Treatment of Multiple Primary Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Review
- Unraveling Tumor-to-Tumor Metastasis: Insights into Pathogenesis, Diagnostic Challenges, and Treatment Modalities.Biologics : targets & therapy · 2025Review
- Navigating the Complexities of Radiation Injuries: Therapeutic Principles and Reconstructive Strategies.Journal of personalized medicine · 2024Review
- Stereotactic ablative brachytherapy versus percutaneous microwave ablation for early-stage non-small cell lung cancer: a multicenter retrospective study.BMC cancer · 2024Article
- Addressing the unmet need in NSCLC progression with advances in second-line therapeutics.Exploration of targeted anti-tumor therapy · 2024Review
- Immune Priming with Spatially Fractionated Radiation Therapy.Current oncology reports · 2023Review
- Efficacy and safety analysis in metastatic cancer patients treated with multiple courses of repeat radiation therapy.Clinical and translational radiation oncology · 2023Article
- Lipid Polyunsaturated Fatty Acid Chains in Mouse Kidneys Were Increased within 5 min of a Single High Dose Whole Body Irradiation.International journal of molecular sciences · 2023Article
- Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases.European journal of medical research · 2023Review
- Outcomes in dogs undergoing surgical stabilization and non-stereotactic radiation therapy for axial and appendicular bone tumors.Frontiers in veterinary science · 2023Article
- Optimizing the synergy between stereotactic radiosurgery and immunotherapy for brain metastases.Frontiers in oncology · 2023Review
- Photon-based high-dose single-fraction radiosurgery, an effective treatment modality for recurrent uveal melanoma.Contemporary oncology (Poznan, Poland) · 2023Article
- Recommendations for stereotactic body radiation therapy for spine and non-spine bone metastases. A GETUG (French society of urological radiation oncolgists) consensus using a national two-round modified Delphi survey.Clinical and translational radiation oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy (RT) has been developed with remarkable technological advances in recent years. The accuracy of RT is dramatically improved and accordingly high dose radiation of the tumors could be precisely projected. Stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), are rapidly becoming the accepted practice in treating solid small sized tumors. Compared with the conventional fractionation external beam radiotherapy (EBRT), SABR with very high dose per fraction and hypo-fractionated irradiation yields convincing and satisfied therapeutic effects with low toxicity, since tumor cells could be directly ablated like radiofrequency ablation (RFA). The impressive clinical efficacy of SABR is greater than expected by the linear quadratic model and the conventional radiobiological principles, i.e., 4 Rs of radiobiology (reoxygenation, repair, redistribution, and repopulation), which may no longer be suitable for the explanation of SABR's ablation effects. Based on 4 Rs of radiobiology, 5 Rs of radiobiology emphasizes the intrinsic radiosensitivity of tumor cells, which may correlate with the responsiveness of SABR. Meanwhile, SABR induced the radiobiological alteration including vascular endothelial injury and the immune activation, which has been indicated by literature reported to play a crucial role in tumor control. However, a comprehensive review involving these advances in SABR is lacking. In this review, advances in radiobiology of SABR including the role of the 4 Rs of radiobiology and potential radiobiological factors for SABR will be comprehensively reviewed and discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.